GLPwatch
In persons with obesity, exercise plus liraglutide improved weight-loss maintenance vs. exercise or placebo.
Ann Intern Med · 2021
Last updated 2026-05-28In a study of 195 adults with obesity, combining the GLP-1 drug liraglutide (3.0 mg daily) with exercise led to better weight-loss maintenance over 52 weeks compared to exercise alone or placebo. Participants using liraglutide maintained an average of 13.1% of their initial weight loss, while those in the exercise-only group maintained 7.7% and the placebo group maintained 3.9%.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2021 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.17 |
| NIH percentile | 11 |
| Molecules | liraglutide |
| Conditions studied | Obesity |
Abstract
Lundgren JR, Janus C, Jensen SBK, et al. N Engl J Med. 2021;384:1719-30. 33951361.
Verbatim abstract via PubMed 34487446 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.